The FDA Must End Unnecessary Drug Trials | Opinion

Access to life-saving medicines remains elusive for countless patients grappling with cancer, autoimmune disorders, and chronic conditions. Regulators can alleviate this issue by discontinuing redundant biosimilar clinical trials when robust scientific evidence already attests to similarity. Each unnecessary study incurs costs, prolongs competition, and keeps vital medicines out of patients' reach.

This predicament transcends pharmaceutical policy discourse; it is a litmus test of whether regulatory frameworks prioritize patient welfare or uphold the status quo.

Biosimilars, biologic medicines manufactured through living systems, have revolutionized modern medicine. The U.S. Food and Drug Administration (FDA) delineates biosimilars as highly similar to approved biologic medicines, with no clinically significant differences in safety, purity, and potency. These medications can offer affordable treatment options, though price reductions are not guaranteed.

Nevertheless, development remains costly, and access is profoundly inequitable. The World Health Organization (WHO) reports that nearly one-third of the global population lacks consistent access to essential medicines, exacerbating the challenge of obtaining advanced biologic treatments even in affluent nations. Uninsured and underinsured patients in wealthy countries confront the harrowing choice between treatment and financial survival.

Advancements in science necessitate regulatory reforms. In March, the FDA unveiled draft recommendations to streamline specific pharmacokinetic (PK) testing requirements, projecting potential cost savings of up to 50 percent, or roughly $20 million. This followed October 2025 draft guidance suggesting that comparative efficacy studies might be redundant when other evidence sufficiently substantiates biosimilarity.

These developments represent progress, but they must form part of a wider international commitment to evidence-based regulation. While the FDA's announcement is a promising signal, draft guidance alone is insufficient. Global regulators must translate this principle into consistent rules, timelines, and transparent decisions that both patients and manufacturers can depend upon.

Conducting a clinical trial becomes ethically justifiable only when it can potentially enhance our understanding or alter a regulatory decision. Sophisticated analytical methods can meticulously compare a biologic's molecular structure, purity, and functional properties. Pharmacokinetic studies can elucidate how a medicine traverses the body.

Should these findings, coupled with appropriate safety and immunogenicity assessments, establish biosimilarity, an additional efficacy trial might contribute minimal valuable information. Consider this analogy: weighing a diamond with an electronic balance and then weighing it again on a household scale— the second measurement does not enhance the first; it merely introduces uncertainty.

Why subject medicine to a similar exercise when superior scientific evidence already resolves the query?

My stance is not that every trial is unnecessary; residual uncertainty warrants investigation, and safety cannot be compromised. However, subjecting patients to trials merely to fulfill an administrative checklist is not rigorous. It is an egregious misuse of science, time, and human participants. The ramifications are not mere theory.

Oncology patients and those afflicted with severe chronic illnesses may languish for years awaiting affordable alternatives while manufacturers bear significant development expenses. Studies offering negligible meaningful information can incur tens of millions of dollars. These expenditures act as deterrents to entry, shielding established brands from competition.

History bears witness to this conundrum. Genetic engineering once evoked dire predictions and vehement opposition. Yet biotechnology progressed, generics proliferated, and the pharmaceutical landscape evolved. Biosimilars should mirror this trajectory. When more qualified manufacturers enter the market, competition can drive prices down and render essential treatments accessible to a broader populace.

Envision a future where regulators scrutinize the entirety of evidence, manufacturers invest in efficient production, and multiple suppliers vie based on quality and price. Medicines currently financially out of reach could become routine treatment in the near future. Conversely, the alternative is a system where preventable suffering persists due to institutions confusing caution with repetition, while patients foot the bill for the delay.

The FDA, the European Medicines Agency, and other regulatory entities must now act. They should harmonize evidence-based guidelines that exclude routine animal toxicity and comparative human efficacy studies when scientifically warranted, while preserving rigorous analytical, pharmacokinetic, immunogenicity, and other crucial safety evaluations.

Clear criteria must also be established for when additional studies genuinely influence a decision. Manufacturers, for their part, must invest in advanced analytical methods and transparent evidence, rather than simply advocating for expedited approvals. Patient advocacy groups and lawmakers must urge regulators to measure success by safety, access, development time, and competition, not by the volume of tests conducted.

A delayed biosimilar is a denied biosimilar. Every avoidable delay exacts a human cost. We already possess the scientific tools to advance further. Regulators must deploy these tools, for patients merit evidence-based decisions, not bureaucratic endurance tests. Dr. Sarfaraz K. Niazi, a pharmaceutical scientist, author, inventor, and affiliate professor at Washington State University, emphasizes that the views articulated herein are his own.